Relay Therapeutics, Inc. (RLAY)

6.11 -0.10 (-1.61%) At close: 04:00PM EDT

Relay Therapeutics, Inc.

399 Binney Street
2nd Floor
Cambridge, MA 02139
United States
617 370 8837
https://www.relaytx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 323

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Alexis A. Borisy A.M.	Co-Founder & Independent Chairman	85k	N/A	1972
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS	CEO, President & Director	1.03M	4.48M	1974
Dr. Mark Murcko Ph.D.	Co-Founder & Director	50k	N/A	1960
Mr. Thomas Catinazzo	Chief Financial Officer	599.83k	1.02M	1977
Mr. Brian R. Adams J.D.	Chief Legal Officer & Secretary	598.53k	N/A	1974
Dr. Donald A. Bergstrom M.D., Ph.D.	President of Research & Development	711.25k	3.39M	1972
Mr. Peter Rahmer	Chief Corporate Development Officer	570.52k	519.96k	N/A
Dr. Deborah Palestrant M.B.A., Ph.D.	Vice President of Corporate Development & Strategy	N/A	N/A	N/A
Mr. Jim Watters Ph.D.	Chief Scientific Officer of Late Research	N/A	N/A	N/A
Dr. Beni B. Wolf M.D., Ph.D.	Chief Medical Officer & Head of Precision Medicine	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Relay Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.